Hyperfine (HYPR) Net Cash Flow Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -54.17% |
| 10 | Hyperfine | 90.12 Mn | 45.35 Mn | 1.98 Mn | 143.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143.82% |
| Mar 31, 2026 | 226.50% |
| Dec 31, 2025 | 268.60% |
| Sep 30, 2025 | 54.66% |
| Jun 30, 2025 | 15.32% |
| Mar 31, 2025 | 67.15% |
| Dec 31, 2024 | 18.26% |
| Sep 30, 2024 | 12.52% |
| Jun 30, 2024 | 4.36% |
| Mar 31, 2024 | 6.69% |
| Dec 31, 2023 | 34.39% |
| Sep 30, 2023 | 31.02% |
| Jun 30, 2023 | 41.73% |
| Mar 31, 2023 | 51.07% |
| Dec 31, 2022 | -112.68% |
| Sep 30, 2022 | -33.13% |
| Jun 30, 2022 | -84.07% |
| Mar 31, 2022 | -217.16% |